More accurate diagnosis on the horizon...

More accurate diagnosis on the horizon...

Posted 09 May, 2022 at 16:04

Author Jessica McClory on behalf of In Sues Name


The critical role of genomic profiling in diagnosing and grading brain tumours has been underscored in a study where brain tumour patients survived for longer when they were treated aggressively with surgery, radiation and chemotherapy

This new, more accurate diagnosis comes from profiling of the DNA alterations that drive tumour growth. All patients underwent genomic sequencing using the UCSF500 Cancer Gene Panel and were offered treatment consistent with a conventional glioblastoma. The length of their survival was compared with a retrospective cohort of 130 glioblastoma patients whose treatment regimens were more conservative, in line with the previous tumour classification. The first group of patients survived an average of 24 months, while the second group survived an average of 16 months.

The researchers reported their study in Neuro-Oncology

More from In Sues Name

New cancer treatment making headway
Press Release

New cancer treatment making headway

21 May 2022
Stronger treatments for glioblastoma
Press Release

Stronger treatments for glioblastoma

18 May 2022
Join our Golf Day this June!
Press Release

Join our Golf Day this June!

16 May 2022
Join our Golf Day in June
Press Release

Join our Golf Day in June

23 April 2022
Card image cap
user

In Sues Name

Charity

Profile Feed
In Sue’s Name was founded in 2014 by David Taylor in memory of his beloved daughter Sue Blasotta, who died in 2011 of brain tumours. Sue was devoted to her husband Joe and their children Sasha and Daniel. She adored her career, first in recruitment with Reed Employment and then caring for ch...

59

Press Releases